# US 2021/0275565 A1 · Compositions comprising circular polyribonucleotides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275565 A1
- Document ID: US20210275565A1
- Status: Published application
- Kind: A1
- Application number: 17/313,963
- Filed: 2021-05-06
- Published: 2021-09-09
- Earliest claimed: 2017-12-15
- Assignees: Flagship Pioneering Innovations VI, LLC
- Applicants: Flagship Pioneering Innovations Vi, LLC
- Inventors: Alexandra Sophie DE BOER; Avak KAHVEJIAN; Nicholas McCartney PLUGIS; Erica Gabrielle WEINSTEIN; Sebastian TROUSIL; Morag Helen STEWART; Ki Young PAEK; Catherine CIFUENTES-ROJAS
- Web page: https://patentgrep.com/patent/US20210275565A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- C07K 7/00: Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K 7/06: having 5 to 11 amino acids
- C12N 15/67: General methods for enhancing the expression
- C12N 15/85: for animal cells
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates generally to pharmaceutical compositions and preparations of circular polyribonucleotides and uses thereof.

## Claims

### Claim 1

A method of expressing a polypeptide in a subject, comprising:
administering to the subject a covalently closed polyribonucleotide that: (a) comprises an internal ribosome entry site (IRES) element; (b) comprises an expression sequence that encodes the polypeptide and that lacks one or both of a 5′ cap and a poly-A sequence; and (c) comprises a termination element; and
translating the polypeptide from the expression sequence of the covalently closed polyribonucleotide in vivo over a period of at least 7 days.

### Claim 2 (depends on 1)

The method of claim 1, wherein the polypeptide is a therapeutic polypeptide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the covalently closed polyribonucleotide further comprises at least one element selected from:
(a) an encryptogen;
(b) a regulatory element; and
(c) a quasi-double-stranded secondary structure.

### Claim 4 (depends on 1)

The method of claim 1, wherein the internal ribosome entry site element comprises a sequence derived from picornavirus complementary DNA, encephalomyocarditis virus (EMCV) complementary DNA, poliovirus complementary DNA, or an Antennapedia gene from Drosophila melanogaster.

### Claim 5 (depends on 1)

The method of claim 1, wherein the termination element comprises a stop codon.

### Claim 6 (depends on 1)

The method of claim 1, wherein the covalently closed polyribonucleotide comprises two or more of the expression sequence encoding the polypeptide.

### Claim 7 (depends on 1)

The method of claim 1, wherein the covalently closed polyribonucleotide further comprises a second expression sequence encoding a second polypeptide.

### Claim 8 (depends on 1)

The method of claim 1, wherein the polypeptide comprises at least 150 amino acids.

### Claim 9 (depends on 1)

The method of claim 1, wherein the polypeptide is an antigen.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antigen is a viral antigen, a bacterial antigen, or a tumor antigen.

### Claim 11 (depends on 1)

The method of claim 1, wherein the polypeptide is at least a functional portion of a viral envelope protein.

### Claim 12 (depends on 1)

The method of claim 1, wherein the polypeptide is selected from the group consisting of a hormone, a cytokine, a ligand, a receptor, an antibody, and an enzyme.

### Claim 13 (depends on 1)

The method of claim 1, wherein the polypeptide is a secreted protein.

### Claim 14 (depends on 1)

The method of claim 1, wherein the polypeptide is an epigenetic modifying agent.

### Claim 15 (depends on 1)

The method of claim 1, wherein the polypeptide is an epigenetic enzyme.

### Claim 16 (depends on 1)

The method of claim 1, wherein the polypeptide is a nuclease.

### Claim 17 (depends on 1)

The method of claim 1, wherein the polypeptide is a component of a CRISPR system.

### Claim 18 (depends on 1)

The method of claim 1, wherein the polypeptide is a nuclease and the covalently closed polyribonucleotide further comprises a guide RNA sequence.

### Claim 19 (depends on 1)

The method of claim 1, wherein the polypeptide is selected from the group consisting of a pore forming peptide, a cytotoxic peptide, and an anti-microbial peptide.

### Claim 20 (depends on 1)

The method of claim 1, wherein the covalently closed polyribonucleotide further comprises an encryptogen.

### Claim 21 (depends on 20)

The method of claim 20, wherein the encryptogen comprises a splicing element, a modified ribonucleotide, or a protein binding site.

### Claim 22 (depends on 20)

The method of claim 20, wherein the encryptogen comprises an immunoprotein binding site.

### Claim 23 (depends on 1)

The method of claim 1, wherein the covalently closed polyribonucleotide is formulated, for the administration, with:
a) a pharmaceutically acceptable excipient;
b) a polymeric carrier;
c) an exosome;
d) a lipid carrier; or
e) a lipid nanoparticle.

### Claim 24 (depends on 1)

The method of claim 1, wherein the covalently closed polyribonucleotide further comprises a miRNA target sequence.

### Claim 25 (depends on 1)

The method of claim 1, further comprising detecting expression of the expression sequence in a cell or a tissue of the subject before and/or after the administration.

### Claim 26 (depends on 1)

The method of claim 1, further comprising detecting the polypeptide in the subject over a time period of at least 7 days.

### Claim 27 (depends on 1)

The method of claim 1, further comprising detecting the polypeptide in the subject over a time period of at least 21 days.

### Claim 28 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 29 (depends on 1)

The method of claim 1, wherein the subject is a non-human mammal.

### Claim 30

A method of delivering a therapeutic polypeptide to a human, comprising:
administering to the human a covalently closed polyribonucleotide that: (a) comprises an internal ribosome entry site (IRES) element; (b) comprises an expression sequence that encodes the therapeutic polypeptide and that lacks one or both of a 5′ cap and a poly-A sequence; and (c) comprises a termination element; and
translating the therapeutic polypeptide from the expression sequence of the covalently closed polyribonucleotide in vivo over a period of at least 7 days,
wherein the therapeutic polypeptide is selected from the group consisting of an antigen, at least a functional portion of a viral envelope protein, a hormone, a cytokine, a ligand, a receptor, an antibody, an enzyme, a secreted protein, an epigenetic modifying agent, a nuclease, a component of a CRISPR system, a pore forming peptide, a cytotoxic peptide, and an anti-microbial peptide.
